Breaking Finance News

Zacks Investment Research downgraded Corium International Inc (NASDAQ:CORI) to Hold in a statement released earlier today.

Zacks Investment Research has downgraded Corium International Inc (NASDAQ:CORI) to Hold in a statement released on Monday June 05, 2017.

Boasting a price of $7.49, Corium International Inc (NASDAQ:CORI) traded 4.80% higher on the day. With the last stock price close down 35.22% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Corium International Inc has recorded a 50-day average of $10.04 and a two hundred day average of $7.59. Volume of trade was down over the average, with 128,207 shares of CORI changing hands under the typical 157,527

Performance Chart

Corium International Inc (NASDAQ:CORI)

With a total market value of $0, Corium International Inc has with a one year low of $2.67 and a one year high of $11.37 .

A total of 6 equity analysts have released a research note on CORI. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $14.67.

Brief Synopsis About Corium International Inc (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.